Phase I/II Study of Weekly Irinotecan and Paclitaxel in Patients With SCLC
Published: | Updated:
This phase I/II nonrandomized, open-label study was designed to assess the safety and benefit of sequencing irinotecan (Camptosar, CPT-11) plus paclitaxel (Taxol) immediately after cisplatin (Platinol)/etoposide (VePesid,